相关实验视频

Updated: Jul 10, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

发现EGFR选择性的4,6-非替代型pyrimidines来自组合性激酶导向的异环库

Qiong Zhang¹, Yi Liu, Feng Gao

¹Departments of Chemistry and Cell Biology, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA.

Journal of the American Chemical Society

|February 16, 2006

概括

研究人员发现了新的胺基药物,可以选择性地抑制表皮生长因子受体 (EGFR) 氨酸激酶. 这些化合物为癌症治疗提供了对现有的纳类药物有希望的替代品.

科学领域:

药用化学医学化学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

皮表皮生长因子受体 (EGFR) 氨酸激酶是癌症药物开发的关键标,因为它在各种瘤中过度表达.
现有的EGFR抑制剂,主要是基纳胺基的,面临局限性,突出了替代化学支架的需要.
选择性抑制EGFR激酶活性至关重要,以最大限度地减少非目标效应并改善治疗结果.

研究的目的:

发现强效和选择性的EGFR激酶抑制剂的新型化学类.
为了探索4,6-非替代型胺衍生物作为潜在的治疗药物,以对抗EGFR驱动的癌症.
阐明这些胺抑制剂观察到的选择性的结构基础.

主要方法:

设计和合成一个库的4,6-非替代的pyrimidine化合物.
试验室酶体测试以评估对EGFR激酶的抑制功效.
细胞测试以评估EGFR信号通路和细胞增殖的抑制.
结构-活动关系 (SAR) 研究和计算建模以了解选择性.

主要成果:

鉴定强效的4,6-异位胺抑制剂,显示出对EGFR的显著酶和细胞活性.
证明了EGFR对其他相关激酶的高选择性,这表明非标毒性潜在降低.
阐明了有助于EGFR激酶域的选择性结合和抑制的关键结构特征.

结论:

4,6-非替代型金字胺是一种新且有效的化学支架,用于开发选择性EGFR抑制剂.
这些发现为当前疗法提供了有希望的替代方案,并为癌症治疗中的临床应用提供了进一步的研究.
对选择性机制的详细理解可以指导下一代激酶抑制剂的设计.

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...